Clinical Study of Three Plus Two Type Early Diagnosis of Pulmonary Nodules in Medical Internet of Things

Medical The Internet of Things (IoT), a recent breakthrough in communication technology, could be helpful in improving health care delivery and saving medical costs, but regarding pulmonary nodule management it is still at the basic understanding. Investigators adopt "Internet of things medical three plus two type pulmonary nodule diagnosis" which chun-xue Bai put forward, used a developed a mobile phone-based IoT (mIoT) platform and initiated a randomized, multicenter, controlled trial to value clinical effectivity of "Internet of things medical three plus two type pulmonary nodule diagnosis" in the management of pulmonary nodules. In this study, at least 600 patients with pulmonary nodules (no typical symptoms, often single, clear boundary, increased density, soft tissue shadow surrounded by lung parenchyma with diameter ≤3 cm) will be randomly allocated to the control group, which receives routine follow-up, or the intervention group, which receives "Internet of things medical three plus two type pulmonary nodule diagnosis" management. Endpoints of the study include: (1) The positive diagnosis rate of lung cancer in I stage; (2) 5 year disease-free survival rate and overall survival rate; (3) direct medical costs per year. Results from this study should provide direct evidence for the suitability of "Internet of things medical three plus two type pulmonary nodule diagnosis" in pulmonary nodules patients management.

Sex

All

Minimum age

18 Years

Subjects must meet the following criteria:

Inclusion Criteria:

1. Over 18 years old;
2. Single or multiple round solitary pulmonary nodules surrounded by lung parenchyma without associated atelectasis, diameter \< 3 cm of small pulmonary nodules;
3. Patients should be capable of reading and writing Chinese, without impaired verbal communication;
4. Patients should be capable of using intellectual equipment.

Exclusion criteria:

1. Chest CT present lung mass, large seepage or atelectasis;
2. Other active chronic respiratory system diseases needing be diagnosed , intervention and treatment;
3. Severe or uncontrolled complications of other systems;
4. Complicated with pleural effusion;
5. Patients with cognitive impairment or mental abnormalities being unable to complete the questionnaire.